Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial
Kerstin Mezger MD1#, Sabine Ebert MD1#, Hannah Elisa Muhle MD1, Udo zur Stadt PhD1, Arndt Borkhardt2, Dagmar Dilloo MD 3 Jörg Faber MD 4, Tobias Feuchtinger MD 5, Thomas Imschweiler MD6, Norbert Jorch MD 7, Arnulf Pekrun MD 8, Irene Schmid MD 5, Franziska Schramm MD1, Martin Zimmermann PhD9, Martin A Horstmann MD1,* and Gabriele Escherich MD1,*
1University Medical Centre Hamburg-Eppendorf, Clinic of Paediatric Haematology and Oncology, Hamburg, Germany
2Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty Duesseldorf, Duesseldorf, Germany;
3Department of Pediatric Hematology/Oncology, University Hospital Bonn, Bonn, Germany.
4Department of Pediatric Hematology/Oncology, University Hospital Mainz, Mainz, Germany.
5Dr. von Hauner Children’s Hospital, Ludwig Maximilian University, Munich, Germany.
6Department of Pediatric Hematology and Oncology, Helios Hospital, Krefeld, Germany.
7Department of Pediatric Hematology and Oncology, Hospital Bielefeld, Germany.
8Department of Pediatric Hematology and Oncology, Hospital Bremen-Mitte, Germany.
9Department of Pediatric Haematology and Oncology, Medical School Hannover, Hannover, Germany
# shared first authorship
* shared last authorship
Corresponding author:
PD Dr. med. Gabriele Escherich Clinic of Paediatric Haematology and Oncology University Medical Centre Hamburg-Eppendorf Martinistraße 52 20246 Hamburg Tel.: 040 74105 3796 Fax.: 040 74105 8101
escherich@uke.de
Word count abstract: 246 words
Word count main text: 2758 words
Number of tables: 3 tables
Number of figures: 4 figures
Supporting information material: 6 supplemental figures, 1 supplemental table
Short running title: Amsacrine in pediatric ALL therapy
Key words: Amsacrine, acute lymphoblastic leukemia, children